Overview
- Quarterly revenue reached $17.56 billion and adjusted earnings were $0.66 per share, both ahead of LSEG estimates, helped by Eliquis and RSV vaccine Abrysvo.
- Pfizer recorded a net loss of about $1.6 billion due to roughly $4.4 billion in asset impairments, and shares fell around 3.2% following the results.
- Covid-19 products continued to fade, with Comirnaty revenue down about 35% and Paxlovid sales down roughly 75% year over year.
- The company reaffirmed 2026 guidance of $59.5 billion to $62.5 billion in revenue and $2.80 to $3.00 in adjusted EPS, plans no share buybacks, expects $10.5 billion to $11.5 billion in R&D, and targets about $7.7 billion in cost savings by end-2027.
- Pfizer underscored pipeline momentum with roughly 20 pivotal trial starts in 2026, about half in ultra‑long‑acting obesity assets from the $10 billion Metsera acquisition, and reported a monthly GLP‑1 candidate met a Phase IIb weight‑loss goal ahead of planned Phase III trials.